Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, the addition of a SULT1A1 enzyme booster to daily 5% minoxidil treatment significantly increased hair regrowth in men with androgenic alopecia compared to minoxidil alone.

This article discusses potential links between male balding, specifically androgenic alopecia, and severe COVID-19, suggesting that balding may serve as a biomarker for identifying higher-risk patients, but it reports no new experimental findings.

In this study, researchers found that the variability in growth factor expression, particularly TGFβ1, in PRP samples could influence patient responses to hair loss treatment with PRP therapy.

This review discusses recent advancements in bone tissue engineering, emphasizing a shift from passive to smart responsive antibacterial strategies to prevent implant-associated infections, and highlights AI's role in optimizing bone scaffold design for personalized, infection-free implants.

This study evaluated AI chatbots' responses to scabies-related questions, finding DeepSeek had the highest accuracy despite higher hallucination rates, while ChatGPT-5.2 provided more readable and reliable information, highlighting variability and the need for cautious use of AI in health queries.

In this study, tofacitinib and baricitinib showed similar effectiveness and safety in treating alopecia areata, but baricitinib had a higher rate of early responders. Baseline hair loss severity was identified as the only independent predictor of treatment response.

This abstract reports pooled safety data from the WILLOW study for participants with cutaneous lupus erythematosus and systemic lupus erythematosus but does not provide new findings.

This case report highlights significant improvement in a patient with severe alopecia areata who responded well to ivarmacitinib after a suboptimal response to another JAK inhibitor, tofacitinib, suggesting ivarmacitinib as a potential alternative for tofacitinib-refractory cases.

In this study, photobiomodulation therapy applied twice weekly for 12 weeks significantly improved hair regrowth and quality of life in alopecia areata patients, with no noted side effects.

This article explores how the integrated stress response and senescence-associated secretory phenotype influence stem cell fate decisions, highlighting their dual roles in both protecting and disrupting stem cell integrity.

In this retrospective study, researchers reported that low-dose oral minoxidil significantly improved hair density in 60 patients with androgenetic alopecia or telogen effluvium over 4-8 months, as detected through standardized AI-powered imaging.

This study explores the design of responsive drug carriers based on the tumor microenvironment to improve targeting and reduce side effects in cancer treatment, using a model of delivering curcumin with a responsive polymer carrier and evaluating potential errors due to cancer cell heterogeneity.

In this study, a patient with severe alopecia areata showed significant hair regrowth after 15 months of partial response to baricitinib and oral minoxidil, following the addition of dupilumab to their treatment regimen.

In this study, researchers used two dermal papilla spheroid models to investigate hair cycle regression mechanisms and found that the vascular system enhances tissue physiology and gene modulation, while Retinol-based treatments can partially recover tissue degeneration observed over an extended culture period.

This study found that patients with alopecia areata showing low treatment burden responded better to baricitinib compared to those with higher previous systemic treatment exposure.

This study found that 45.5% of alopecia areata patients treated with ritlecitinib 50 mg daily achieved significant hair regrowth, with most maintaining their response over 24 months.

This study reviewed evidence on the role of specific genes (FKBP12, SAMAHD1, TRF2, CD155, and GATA3) in predicting how breast cancer patients might respond to adjuvant chemotherapy, aiming to monitor these markers in blood or tissue samples.

In this study, the authors reported a case of alopecia X in a German Spitz dog and found that treatment with orchiectomy and melatonin resulted in partial hair regrowth and improved the dog's dermatological condition.

This study found that adding a SULT1A1 enzyme booster to minoxidil treatment improved hair growth response in 65% of androgenetic alopecia patients who were previous non-responders to minoxidil alone, with females benefiting more than males.

This study found that patients with higher baseline monocyte counts (\(\geq\) 925/\(\mu\)l) were significantly more likely to see treatment failure with adalimumab for hidradenitis suppurativa.

This case report describes a 21-year-old woman with circumscribed alopecia areata incognita, who experienced a sustained positive response to treatment with oral tofacitinib after conventional treatments frequently failed to provide lasting effects.

Sex and race affect immune responses and treatment outcomes in Hidradenitis suppurativa.

This case report describes an adolescent boy with congenital triangular alopecia who showed significant hair regrowth after eight months of treatment with 5% topical minoxidil, achieving full coverage of the affected area without adverse effects.

This retrospective cohort study reported that oral tofacitinib was effective in treating alopecia areata, with 83.2% of patients showing improvement and 16.0% achieving complete remission. Earlier intervention and previous hair regrowth were linked to better outcomes, and no severe adverse events were observed.

Increased EGFR gene variations may predict chemotherapy outcomes in small cell lung cancer patients.

This study found that in participants with notalgia paresthetica, 8 weeks of treatment with difelikefalin significantly improved itch intensity and increased the rate of strict complete response compared to placebo, starting as early as week 3.

This review reports that sex-related differences in pharmacological response have been observed in SARS-CoV-2 infection, dyslipidemia, and diabetes mellitus, with implications for treatment strategies; for example, men may respond better to genomic vaccines for SARS-CoV-2, while women may benefit more from certain antiviral medications.

This study explored COVID-related chilblains using transcriptomics and found they showed a distinct interferon and JAK/STAT pathway activation, absent in vaccine-related chilblains, with inflammatory cell types varying over time.